{"organizations": [], "uuid": "605f86d69b8fa750df45ce554e6c35161358617d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-exelixis-says-phase-3-imblaze370-s/brief-exelixis-says-phase-3-imblaze370-study-did-not-meet-its-primary-endpoint-of-improving-overall-survival-vs-regorafenib-idUSASC0A1A9", "country": "US", "domain_rank": 408, "title": "BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T08:10:00.000+03:00", "replies_count": 0, "uuid": "605f86d69b8fa750df45ce554e6c35161358617d"}, "author": "", "url": "https://www.reuters.com/article/brief-exelixis-says-phase-3-imblaze370-s/brief-exelixis-says-phase-3-imblaze370-study-did-not-meet-its-primary-endpoint-of-improving-overall-survival-vs-regorafenib-idUSASC0A1A9", "ord_in_thread": 0, "title": "BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "improving overall survival vs regorafenib reuters", "sentiment": "none"}, {"name": "exelixis", "sentiment": "none"}, {"name": "exelixis inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - Exelixis Inc:\n* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER\n* STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL VERSUS REGORAFENIB\n* GENENTECH INFORMED CO COMBINATION OF ATEZOLIZUMAB AND COBIMETINIB DID NOT DELIVER IMPROVEMENT IN OVERALL SURVIVAL VERSUS REGORAFENIB\n* GENENTECH WILL FURTHER EXAMINE RESULTS FROM IMBLAZE370 AND PLANS TO PRESENT DATA AT AN UPCOMING MEDICAL MEETING Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-05-10T08:10:00.000+03:00", "crawled": "2018-05-10T08:25:28.018+03:00", "highlightTitle": ""}